News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA™ (CR845/difelikefalin) in Chronic Liver Disease (CLD) Patients
Data to inform dose selection for planned Phase 2 trial in CLD-associated pruritus STAMFORD, Conn. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus
View HTML
Toggle Summary Cara Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
STAMFORD, Conn. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
STAMFORD, Conn.,  Jan. 31, 2018  (GLOBE NEWSWIRE) --  Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2017 Financial Results
Management to host conference call today at 4:30 p.m. ET
View HTML
Toggle Summary Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting
STAMFORD, Conn. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017
STAMFORD, Conn. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)
View HTML
Toggle Summary Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation
View HTML
Toggle Summary Cara Therapeutics to Present Data at Kidney Week 2017
STAMFORD, Conn. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML